BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

820 related articles for article (PubMed ID: 25099128)

  • 21. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
    Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A standardized protocol for detection of ALK protein expression and gene fusion in lung adenocarcinoma cytologic specimens].
    Wang Z; Wu X; Shi Y; Han X; Cheng G; Li L; Mu X; Zhang Y; Cui D; Zhang L; Fan Z; Zhu G; Ma L; Yang L; Di J; Liu D
    Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):742-8. PubMed ID: 26813592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.
    Williams AS; Greer W; Bethune D; Craddock KJ; Flowerdew G; Xu Z
    Virchows Arch; 2016 Nov; 469(5):533-540. PubMed ID: 27562706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).
    Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X
    Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
    To KF; Tong JH; Yeung KS; Lung RW; Law PP; Chau SL; Kang W; Tong CY; Chow C; Chan AW; Leung LK; Mok TS
    J Thorac Oncol; 2013 Jul; 8(7):883-91. PubMed ID: 23625156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent.
    Conklin CM; Craddock KJ; Have C; Laskin J; Couture C; Ionescu DN
    J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23196275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anaplastic Lymphoma Kinase Immunocytochemistry on Cell-Transferred Cytologic Smears of Lung Adenocarcinoma.
    Zhang C; Randolph ML; Jones KJ; Cramer HM; Cheng L; Wu HH
    Acta Cytol; 2015; 59(2):213-8. PubMed ID: 25967762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas.
    Lantuejoul S; Rouquette I; Blons H; Le Stang N; Ilie M; Begueret H; Grégoire V; Hofman P; Gros A; Garcia S; Monhoven N; Devouassoux-Shisheboran M; Mansuet-Lupo A; Thivolet F; Antoine M; Vignaud JM; Penault-Llorca F; Galateau-Sallé F; McLeer-Florin A
    Eur Respir J; 2015 Jul; 46(1):207-18. PubMed ID: 25929957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization.
    Wang W; Tang Y; Li J; Jiang L; Jiang Y; Su X
    Cancer Cytopathol; 2015 Feb; 123(2):117-22. PubMed ID: 25529354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas.
    Sholl LM; Weremowicz S; Gray SW; Wong KK; Chirieac LR; Lindeman NI; Hornick JL
    J Thorac Oncol; 2013 Mar; 8(3):322-8. PubMed ID: 23407557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
    Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
    Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer.
    Houang M; Toon CW; Clarkson A; Sioson L; Watson N; Farzin M; Selinger CI; Chou A; Morey AL; Cooper WA; O'Toole SA; Gill AJ
    Pathology; 2014 Aug; 46(5):383-8. PubMed ID: 24842379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.
    Jang JS; Wang X; Vedell PT; Wen J; Zhang J; Ellison DW; Evans JM; Johnson SH; Yang P; Sukov WR; Oliveira AM; Vasmatzis G; Sun Z; Jen J; Yi ES
    J Thorac Oncol; 2016 Nov; 11(11):1891-1900. PubMed ID: 27343444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of ALK gene rearrangement and ALK protein expression in primary lung carcinoma and matched metastasis.
    Trejo Bittar HE; Luvison A; Miller C; Dacic S
    Histopathology; 2017 Aug; 71(2):269-277. PubMed ID: 28316074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH.
    Minca EC; Portier BP; Wang Z; Lanigan C; Farver CF; Feng Y; Ma PC; Arrossi VA; Pennell NA; Tubbs RR
    J Mol Diagn; 2013 May; 15(3):341-6. PubMed ID: 23499337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH.
    Hutarew G; Hauser-Kronberger C; Strasser F; Llenos IC; Dietze O
    Histopathology; 2014 Sep; 65(3):398-407. PubMed ID: 24612196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiplex fluorescence in situ hybridization testing for anaplastic lymphoma kinase and c-ros oncogene 1 gene rearrangements on cytology smears in lung adenocarcinomas: comparative study with formalin-fixed paraffin-embedded sections.
    Nambirajan A; Rana D; Samant K; Prabakaran A; Malik P; Jain D
    J Am Soc Cytopathol; 2022; 11(3):154-164. PubMed ID: 35148960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.
    Pekar-Zlotin M; Hirsch FR; Soussan-Gutman L; Ilouze M; Dvir A; Boyle T; Wynes M; Miller VA; Lipson D; Palmer GA; Ali SM; Dekel S; Brenner R; Bunn PA; Peled N
    Oncologist; 2015 Mar; 20(3):316-22. PubMed ID: 25721120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.
    Wang J; Cai Y; Dong Y; Nong J; Zhou L; Liu G; Su D; Li X; Wu S; Chen X; Qin N; Zeng X; Zhang H; Zhang Z; Zhang S
    PLoS One; 2014; 9(7):e101551. PubMed ID: 24992725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
    Rogers TM; Russell PA; Wright G; Wainer Z; Pang JM; Henricksen LA; Singh S; Stanislaw S; Grille J; Roberts E; Solomon B; Fox SB
    J Thorac Oncol; 2015 Apr; 10(4):611-8. PubMed ID: 25789833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.